{"entity":{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","aka":[],"tldr":"Abdera Therapeutics engineered antibodies that carry a radioactive isotope to cancer cells, tuning how long they circulate so more radiation reaches the tumour and less reaches healthy tissue. Its first medicine targets a protein on small cell lung cancer.","summary":"Abdera Therapeutics, based in Vancouver and Menlo Park, California, developed antibody-based radiopharmaceuticals using its ROVEr antibody engineering platform, which tunes pharmacokinetic properties so that alpha- or beta-emitting isotopes can be matched to targets with a wide range of antigen expression. Its lead programme targets DLL3 for small cell lung cancer and other solid tumours and was advancing toward the clinic at launch; founding partners were adMare BioInnovations and AbCellera. The company emerged in April 2023 with USD 142 million in combined Series A and B financing, the Series A led by Versant Ventures and Amplitude Ventures and the USD 110 million Series B led by venBio Partners with Viking Global Investors, Qiming Venture Partners USA and RTW Investments.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer"},{"label":"Endpoints News: Abdera raises $110M Series B","url":"https://endpoints.news/abdera-raises-110m-to-push-targeted-radiotherapies-where-they-havent-gone-before/"}],"tags":[],"related":["src-endpoints-news"],"cancers":["sclc"],"sections":["radiopharma"],"technologies":["radioimmunotherapy","targeted-alpha-therapy","radioligand-therapy"],"targets":["dll3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website abderatx.com returned HTTP 503 or no response on every attempt, so the website field points to the fetched press release copy instead. Current status is uncertain: search headlines in 2026 refer to an auction of Abdera laboratory equipment and to biotechs that closed, but no fetched primary source confirms a wind-down, so stage is left at startup. Clinical status of the DLL3 programme (a phase 1a start was reported in trade press) not confirmed from fetched pages."],"hq":"Vancouver","country":"CA","companyType":"radiopharma","website":"https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer","stage":"startup","investors":["versant-ventures"],"funding":[{"round":"Series B","year":2023,"amountUsd":110000000,"source":"https://endpoints.news/abdera-raises-110m-to-push-targeted-radiotherapies-where-they-havent-gone-before/","note":"Led by venBio Partners; the company's launch release reports USD 142 million in combined Series A and B financing"}]},"route":"/companies/abdera-therapeutics/","neighbours":{"collection":[{"id":"src-endpoints-news","kind":"collection","name":"Endpoints News","route":"/collections/src-endpoints-news/"}],"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"}],"company":[{"id":"versant-ventures","kind":"company","name":"Versant Ventures","route":"/companies/versant-ventures/"}]}}